NCT00015964|CompletedPhase 2
ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck
A Phase II Stdy of ZD 1839 in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Loading search results
A Phase II Stdy of ZD 1839 in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Sponsor study identifier
Secondary identifiers
interventional
51
1 country
11
Study Start
March 2001
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
September 2001
Actual (reported)Study Completion
July 2005
Actual (reported)RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of head and neck cancer. PURPOSE: Phase II trial to study the effectiveness of ZD1839 in treating patients who have metastatic or recurrent cancer of the head and neck.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 2005
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 2001
Date type not reportedThis date has not been verified as actual or estimated.
May 6, 2001
Actual (reported)September 2001
Actual (reported)February 27, 2004
Actual (reported)July 2005
Actual (reported)Early response rates of ZD1839 in head and neck tumors
2 months
University of Chicago Cancer Research Center
Chicago, Illinois, 60637-1470, United States
Louis A. Weiss Memorial Hospital
Chicago, Illinois, 60640, United States
Cancer Care Specialists of Central Illinois, S.C.
Decatur, Illinois, 62526, United States
Evanston Northwestern Health Care
Evanston, Illinois, 60201, United States
Ingalls Memorial Hospital
Harvey, Illinois, 60426, United States
Columbia LaGrange Memorial Hospital
LaGrange, Illinois, 60525, United States
Loyola University Medical Center
Everett Vokes, MD
University of Chicago
51 participants (actual enrollment reported by the registry).
First Submitted
May 6, 2001
First Posted
February 27, 2004
Study Start
March 2001
Date type not reportedThis date has not been verified as actual or estimated.
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Maywood, Illinois, 60153, United States
Oncology/Hematology Associates of Central Illinois, P.C.
Peoria, Illinois, 61602, United States
Fort Wayne Medical Oncology and Hematology, Inc.
Fort Wayne, Indiana, 46885-5099, United States
Michiana Hematology/Oncology P.C.
South Bend, Indiana, 46617, United States
Oncology Care Associates, P.L.L.C.
Saint Joseph, Michigan, 49085, United States
Primary Completion
September 2001
Actual (reported)Study Completion
July 2005
Actual (reported)Last Updated
September 5, 2013
Record last verified: 2013-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: